A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.

Also called NCT07351058

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07351058
  • EU CT 2025-523106-32-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, India, Italy, Japan, Mexico, Poland, Puerto Rico, Romania, South Korea, Spain, Taiwan, Thailand, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07351058. Randomized; double masking; primary purpose treatment. Start 2026-03-23 (actual); primary completion 2028-08-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Acronym
Enith2
Condition
Obesity or Overweight
Condition
Type 2 Diabetes Mellitus
Intervention (Combination product)
Placebo
Intervention (Combination product)
Enicepatide
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct07351058
Content hash
a50fc7c392f997678e878a40e2b89eef67d84d428db9bd88a45cb1c049ef6da2